174 related articles for article (PubMed ID: 27967336)
1. What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?
Diekstra MH; Liu X; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Jan; 18(1):1-4. PubMed ID: 27967336
[No Abstract] [Full Text] [Related]
2. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
3. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
4. Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Kakoki K; Miyata Y; Mochizuki Y; Iwata T; Obatake M; Abe K; Nagayasu T; Sakai H
Clin Genitourin Cancer; 2017 Jun; 15(3):e503-e506. PubMed ID: 28190703
[No Abstract] [Full Text] [Related]
5. Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?
Procopio G; Verzoni E; Guadalupi V; Iacovelli R; Bajetta E
Tumori; 2010; 96(5):794-5. PubMed ID: 21302633
[No Abstract] [Full Text] [Related]
6. Molecular-targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: A proposed strategy.
Tsuchiya N
Int J Urol; 2019 Jan; 26(1):48-56. PubMed ID: 30276868
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
[No Abstract] [Full Text] [Related]
8. Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.
Brugarolas J
J Natl Compr Canc Netw; 2016 Jul; 14(7):925-7. PubMed ID: 27407131
[No Abstract] [Full Text] [Related]
9. [Biomarker for molecular targeting therapy against renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
[No Abstract] [Full Text] [Related]
10. A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Diekstra MH; Swen JJ; Gelderblom H; Guchelaar HJ
Expert Rev Mol Diagn; 2016; 16(5):605-18. PubMed ID: 26837796
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
13. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapy for renal cell carcinoma].
Terai K; Horie S
Nihon Jinzo Gakkai Shi; 2016; 58(4):568-72. PubMed ID: 27416700
[No Abstract] [Full Text] [Related]
15. Systemic treatment of renal cell cancer: A comprehensive review.
Sánchez-Gastaldo A; Kempf E; González Del Alba A; Duran I
Cancer Treat Rev; 2017 Nov; 60():77-89. PubMed ID: 28898679
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for patients with renal-cell carcinoma.
Rini BI
Lancet Oncol; 2011 Nov; 12(12):1085-7. PubMed ID: 22015058
[No Abstract] [Full Text] [Related]
17. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
Gross-Goupil M; Massard C; Ravaud A
Curr Urol Rep; 2012 Feb; 13(1):16-23. PubMed ID: 22139625
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
20. [Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management].
Nagyiványi K; Géczi L
Orv Hetil; 2017 Sep; 158(38):1488-1502. PubMed ID: 28920717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
